Sox10: A Pan-Schwannian and melanocytic marker

American Journal of Surgical Pathology

Volumn 32, Issue 9, 2008, Pages 1291-1298

  Nonaka, Daisuke ^a,c   Chiriboga, Luis ^a   Rubin, Brian P ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Malignant peripheral nerve sheath tumor; Melanoma; Neural crest; S100 protein; Schwann cell; Sox10

Indexed keywords

TRANSCRIPTION FACTOR SOX10; DNA BINDING PROTEIN; HIGH MOBILITY GROUP PROTEIN; PROTEIN S 100; SOX-10 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARTICLE; ASTROCYTOMA; CARCINOID; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMARY GLAND; MELANOCYTE; MELANOMA; MYOEPITHELIUM CELL; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SALIVARY GLAND; SCHWANN CELL; SENTINEL LYMPH NODE; BIOSYNTHESIS; METABOLISM; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; TISSUE MICROARRAY;

DNA-BINDING PROTEINS; HIGH MOBILITY GROUP PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; NERVE SHEATH NEOPLASMS; S100 PROTEINS; SCHWANN CELLS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 52149114002     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181658c14     Document Type: Article

References (36)

1. Aisner DL, Maker A, Rosenberg SA, et al. Loss of S100 antigenicity in metastatic melanoma. Hum Pathol. 2005;36:1016-1019.
2. Antonescu CR, Nafa K, Segal NH, et al. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma - association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12:5356-5362.
3. Argenyi ZB. Neural tumours. In: Leboit PE, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon: IARC Press; 2006:263-275.
4. Argenyi ZB, Cain C, Bromley C, et al. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol. 1994;16:233-240.
5. Banerjee SS, Harris M. Morphological and immunophenotypic variations in malignant melanoma. Histopathology. 2000;36: 387-402.
6. Bishop PW, Menasce LP, Yates AJ, et al. An immunophenotypic survey of malignant melanomas. Histopathology. 1993;23:159-166.
7. Chorny JA, Barr RJ. S100-positive spindle cells in scars: a diagnostic pitfall in the re-excision of desmoplastic melanoma. Am J Dermatopathol. 2002;24:309-312.
8. Coindre JM, de Mascarel A, Trojani M, et al. Immunohistochemical study of rhabdomyosarcoma. Unexpected staining with S100 protein and cytokeratin. J Pathol. 1988;155:127-132.
9. de Vries E, Elder DE, Bray F, et al. Melanocytic tumours. In: Leboit PE, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon: IARC Press; 2006:49-119.
10. DeLellis RA, Lloyd RV, Heitz PU, et al. Tumours of the thyroid and parathyroid, tumours of the adrenal gland. In: DeLellis RA, Lloyd RV, Heitz PU, et al, eds. Pathology and Genetics, Tumours of Endocrine Organs. Lyon: IARC press; 2004:49-173.
11. Drier JK, Swanson PE, Cherwitz DL, et al. S100 protein immunoreactivity in poorly differentiated carcinomas. Immunohis-tochemical comparison with malignant melanoma. Arch Pathol Lab Med. 1987;111:447-452.
12. Dupin E, Calloni G, Real C, et al. Neural crest progenitors and stem cells. C R Biol. 2007;330:521-529.
13. Gershon TR, Oppenheimer O, Chin SS, et al. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia. 2005; 7:575-584.
14. Guillou L, Wadden C, Kraus MD, et al. S-100 protein reactivity in synovial sarcomas - a potentially frequent diagnostic pitfall. Immunohistochemical analysis of 100 cases. Appl Immunohistochem. 1996;4:167-175.
15. Hamilton SR, Aaltonen LA. Tumours of the stomach, small intestine, colon and rectum. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics, Tumours of Digestive System. Lyon: IARC Press; 2000:37-142.
16. Herrera GA, Turbat-Herrera EA, Lott RL. S-100 protein expression by primary and metastatic adenocarcinomas. Am J Clin Pathol. 1988;89:168-176.
17. Jiao Z, Zhang ZG, Hornyak TJ, et al. Dopachrome tautomerase (Dct) regulates neural progenitor cell proliferation. Dev Biol. 2006;296:396-408.
18. Kelsh RN. Sorting out Sox10 functions in neural crest development. Bioessays. 2006;28:788-798.
19. Kim J, Lo L, Dormand E, Anderson DJ. SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Nqeuron. 2003;38:17-31.
20. Kordes U, Hagel C. Expression of SOX9 and SOX10 in central neuroepithelial tumor. J Neurooncol. 2006;80:151-155.
21. Kordes U, Cheng YC, Scotting PJ. Sox group E gene expression distinguishes different types and maturational stages of glial cells in developing chick and mouse. Brain Res Dev Brain Res. 2005;157: 209-213.
22. Levy P, Vidaud D, Leroy K, et al. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer. 2004;3:20.
23. Miettinen M. Immunohistochemistry of soft tissue tumors. In: Miettinen M, ed. Diagnostic Soft Tissue Pathology. New York: Churchill Livinstone; 2003:54-56.
24. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000;13:1134-1142.
25. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205-211.
26. Owens SE, Broman KW, Wiltshire T, et al. Genome-wide linkage identifies novel modifier loci of aganglionosis in the Sox10Dom model of Hirschsprung disease. Hum Mol Genet. 2005;14:1549-1558.
27. Roh J, Cho EA, Seong I, et al. Down-regulation of Sox10 with specific small interfering RNA promotes transdifferentiation of Schwannoma cells into myofibroblasts. Differentiation. 2006;74: 542-551.
28. Scheithauer BW, Woodruff JM, Erlandson RA. Malignant peripheral nerve sheath tumors. In: Scheithauer BW, Woodruff JM, Erlandson RA, eds. Tumors of the Peripheral Nervous System. Washington, DC: Armed Forces Institute of Pathology; 1999: 303-372.
29. Sciot R, Speleman F. Clear cell sarcoma of soft tissue. In: Fletcher CD, Unni KK, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2000:211-212.
30. Spanknebel K, Coit DG, Bieligk SC, et al. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol. 2005;29:305-317.
31. Swanson PE, Stanley MW, Scheithauer BW, et al. Primary cutaneous leiomyosarcoma. A histological and immunohistochemical study of 9 cases, with ultrastructural correlation. J Cutan Pathol. 1988;15:129-141.
32. Travis WD, Brambilla E, Müller-hermelink HK, et al. Tumours of the lung. In: Travis WD, Brambilla E, Müller-hermelink HK, et al, eds. Pathology and Genetics Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004:9-124.
33. Trefzer U, Hofmann M, Reinke S, et al. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. Melanoma Res. 2006;16:137-145.
34. Wegner M, Stolt CC. From stem cells to neurons and glia: a Soxist's view of neural development. Trends Neurosci. 2005;28: 583-588.
35. Wehrli BM, Huang W, De Crombrugghe B, et al. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondro-sarcoma from other small blue round cell tumors. Hum Pathol. 2003;34:263-269.
36. Woodruff JM, Kourea HP, Louis DN, et al. Tumours of cranial and peripheral nerves. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000:163-174.